Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Test Measures Men's Fertility

By LabMedica International staff writers
Posted on 06 Nov 2018
Male fertility is a serious and growing concern globally. More...
Yet, the field of andrology faces critical gaps in diagnostic technologies and knowledge, affecting scientific advancement as well as clinical management by both reproductive endocrinologists and urologists.

Although effective at identifying descriptive parameters, traditional semen analysis fails to identify defects in sperm function. Put simply, it does not provide information about whether a man's sperm can fertilize an egg, and the probability of that man generating a pregnancy.

A team of scientists working with Cornell University (Ithaca, NY, USA) collected 208 semen samples from men having medical evaluations because of questions regarding their fertility. In addition to undergoing traditional semen analysis, the team tested the samples and assigned them prospectively into groups predicted to have low versus normal fertility. The samples were collected and processed using Cap‐Score Male Fertility Assay kits. Clinical outcomes were later reported for 91 of these men.

The team reported that men with normal Cap-Scores had a 2.78-fold higher chance of pregnancy than men with a low score, and a 4.23-fold higher success rate at achieving pregnancy in their first attempt at intrauterine insemination (IUI). In contrast, none of the elements of semen analysis, such as sperm swimming or concentration, had any relationship with male fertility. The team collected more Cap-Scores and clinical outcomes from a total of five fertility clinics and urology practices and using data from 124 men, the scientists generated a curve that translates a Cap-Score into the probability of generating a pregnancy.

Alexander J. Travis, VMD, PhD, an Associate Professor of Reproductive Biology and senior author of the study, said, “Out of all the tests commonly used to measure sperm, the Cap-Score is the only one that prospectively has been shown to indicate the probability of a man to generate a pregnancy. This new ability to diagnose a man's fertility status and ability to generate a pregnancy will let doctors counsel their patients toward a personalized journey to parenthood, using the approaches most appropriate for them.” The study was published on September 24, 2018, in the journal Molecular Reproduction and Development.

Related Links:
Cornell University


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Calprotectin Assay
Fecal Calprotectin ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.